Scratching the Surface: Understanding Itch in Prurigo Nodularis
Dermatology
Join experts Drs. Raja Sivamani and Sarina Elmariah as they discuss the clinical signs and high patient burden of PN, explore PN pathophysiology, and examine diagnostic challenges.
Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)
Dermatology
Join Drs. Victoria Werth and Teri Greiling as they explain the autoimmunity driving bullous pemphigoid (BP), as well as the important role type 2 inflammation plays in BP.
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Pulmonology
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.
The Journey of Diagnosis: Disease Burden and Diagnostic Considerations for Atopic Dermatitis and Prurigo Nodularis
Dermatology
In this ADVENT symposium at the 2024 Diversity in Dermatology conference, Dr(s) Sarina Elmariah and Mona Shahriari engage in a dynamic discussion on diagnostic considerations and challenges associated with atopic dermatitis and prurigo nodularis.
Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology
Dermatology
Watch Drs. Simpson and Armstrong explore the clinical presentations, diagnostic challenges, and significant burdens experienced by patients with atopic dermatitis and hand and foot dermatitis, as well as the role type 2 inflammation plays in both of these diseases.
Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice
Dermatology
In this ADVENT symposium at the 2024 Diversity in Dermatology conference, experts Dr(s) Sarina Elmariah and Mona Shahriari engage in a dynamic discussion on diagnostic considerations for atopic dermatitis and prurigo nodularis and how clinical signs and itch in these diseases are impacted by type 2 inflammation.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.